The University of Manchester

Rockwell Automation, Inc.

Rockwell Automation Technologies Incorporated

Anthony Day

Derek William Jones

Caroline Milner

Julian Poyner

Paul Bishop

Derek Sawyer

Dick Heinegard

Sheona Patricia Drummond

Afsie Sabokbar

Simon J Clark

Robert B Sim

Anna M Blom

Joo Youn Oh

A magnetic latch for industrial environments includes fixed magnetic pole pieces that may be sealed within a housing to resist environmental contamination and which provide for perpendicular engagement faces for use with gates having a rolling or swinging configuration. An RFID tag reader may be incorporated into the magnet assembly of the latch for reading a specially encoded RFID tag in a keeper portion of the magnetic latch.

Magnetic latch for safety applications with adjustable holding force

A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosed.

Method of treating bone disorders using TSG-6

The invention provides use of a TSG-6 polypeptide, or a polynucleotide encoding an TSG-6 polypeptide, in the manufacture of a medicament for the treatment or prevention of a bone disease or condition associated with bone resorption by osteoclasts.

According to an aspect of the present invention, there is provided a method and apparatus for controlling access to a restricted area containing machinery. The method comprises receiving from a communications device a location identifier associated with said restricted area and a further identifier, verifying said location identifier and said further identifier, and controlling access to said restricted area based upon said verifying. Controlling access to said restricted area comprises providing a control signal to a controller associated with said restricted area. The controller is arranged to control said machinery in response to said control signal.

Access control

The invention relates to identifying agents which have the ability to preferentially inhibit binding to targets such as heparin of the H384 allotypic variant of human complement Factor H, the allotypic variant associated with age-related macular degeneration (AMD), and the non-disease associated form of the same factor (Y384). The targets of interest show differential binding of the two allotypic variants and antagonists thus identified are of interest in developing treatments for AMD.

Screening assays for binding antagonists of the AMD-associated variant of factor H (H384)

Growing community of inventors

Manchester, United Kingdom

Anthony Day